ACRV highlights AP3 AI platform for oncology drug development
ACRV says its AP3 platform supports high-resolution, AI-driven drug development, with lead assets in phase II trials and a preclinical CDK11 inhibitor targeting AML.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.